The company will see the completion of its projects about a year earlier than expected.
Cambrex is ahead of schedule.
The global CDMO revealed that it has almost completed a $100 million investment strategy, according to a press release.1 While the company had initially planned for the strategy to be completed in five years, the current forecast shows it being completed in just four.
The company has added more than 150,000-square-feet of manufacturing space as part of the plan. When the project is completed by the end of 2024, the company expects to have expanded its space and capabilities at 70% of its sites in Europe and North America. These expansions will improve aspects across clinical and commercial drug development.
One of the major aspects of the plan was to add new capabilities for the creation of complex molecules.
By the end of 2024, Cambrex expects to complete projects in Iowa and Sweden. The Iowa project, located in Charles City, add a new modernized quality control laboratory to the company’s portfolio. In Sweden, Cambrex plans to complete two new production lines in Karlskoga.
Cambrex has already completed projects in North America, such as expanded capacity at existing sites in Charles City, Iowa, and High Point, North Carolina. The company also updated the technology at a site in Waltham, Massachusetts, and expanded capabilities at its site in Longmont, Colorado.
In Europe, the company expanded R&D in Milan, Italy, and built a new storage facility in Liege, Belgium.
In a press release, Cambrex’s CEO Tom Loewald said, “When we began this journey, we aligned our investment strategy to the future needs of our pharmaceutical customers. In addition to manufacturing capacity, we invested in specialized technologies to accelerate the development of highly potent APIs and complex synthetic candidates. I'm thrilled to announce that these capabilities and capacity will be available to the market well ahead of schedule, showcasing the efforts of our talented site operations and engineering teams."
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.